-- 瑞银分析师周一在一份报告中指出，雪佛龙（CVX）第一季度的财务业绩预示着其盈利将实现“显著”的环比增长，这一势头将在今年剩余时间和2027年上半年持续增强。 瑞银表示，尽管面临时间因素带来的重大不利影响，雪佛龙第一季度的业绩仍超出预期。 分析师指出，中东冲突并未直接影响雪佛龙的资产，此前因预防措施而关闭的项目现已恢复运营。 瑞银表示，多项潜在因素可能推动雪佛龙第二季度和第三季度的盈利增长，其中包括其位于哈萨克斯坦的TCO项目。该项目目前的产能已超过公布的水平，预计第二季度来自哈萨克斯坦/欧亚大陆的产量将增长60%。 分析师表示，就长期合约量而言，布伦特原油和日本原油混合价格每桶上涨10美元，将带来6亿美元的税前利润和4.5亿美元的税后利润。 瑞银维持对该股的“买入”评级，并将目标价从218美元上调至220美元。
Price: $191.83, Change: $+1.20, Percent Change: +0.63%
(Updates prices.)Gold traded lower midafternoon Monday as the dollar and yields rose, forcing the precious metal below the tight range it has stuck within for the past month.Gold for June delivery was last seen down US$112.20 to US$4,533.20 per ounce, the lowest since March 27.The war on Iran has prompted some safe-haven demand for the metal, even as the higher oil prices that followed the start of the war on Iran is hiking inflation. This is raising concerns higher interest rates are on the way, which is bearish for the metal since it pays no interest."Gold remains supported by safe-haven demand as investors continue to watch the Middle East conflict, oil prices, and the yen. Any durable easing in the Strait of Hormuz would likely cool demand for defensive assets, but until shipping flows normalise, gold should remain sensitive to geopolitical headlines and shifts in real yields," Saxo Bank noted.The dollar rose, with the ICE dollar index last seen up 0.2.9 points to 98.45. Treasury yields were sharply higher, with the U.S. two-year note last seen paying 3.975%, up 8.3 basis points, while the yield on the 10-year note as up 7.0 points to 4.449%
Celcuity (CELC) reported late Friday positive topline results from a cohort of its phase 3 Viktoria-1 trial, with the study meeting its primary endpoint and showing a clinically meaningful improvement in progression-free survival.The study evaluated gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer who had progressed after a CDK4/6 inhibitor and an aromatase inhibitor.Shares jumped more than 16%, with intraday trading volume at over 2.5 million from a daily average of roughly 737,000.CNS Pharmaceuticals (CNSP) shares surged 268% amid heavy trading after the company said Monday it signed deals for a private placement financing likely to generate roughly $22.5 million.Intraday trading volume catapulted to over 78.4 million shares from a daily average of about 32,000.American Express Global Business Travel, which is operated by Global Business Travel Group (GBTG), said Monday it has entered into a definitive agreement to be acquired by Long Lake Management for $9.50 per share in an all-cash deal valued at about $6.3 billion.Shares soared 57%, with intraday trading volume of over 61.6 million from a daily average of about 1.6 million.Price: $146.00, Change: $+20.35, Percent Change: +16.20%
Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.3%.The iShares Biotechnology ETF (IBB) rose 1.3%.In corporate news, Amgen (AMGN) said Monday it will invest an additional $300 million in its biologics manufacturing facility in Puerto Rico. Amgen shares were down 2.1%.Vanda Pharmaceuticals (VNDA) shares jumped past 5% after it said Monday its motion sickness drug Nereus is now commercially available in the US.Eli Lilly (LLY) shares added 0.2% after Barclays lifted the company's price target to $1,400 from $1,350, while keeping its overweight rating.Moderna (MRNA) is showing continued advancement across its pipeline, with progress in cancer vaccines and infectious disease programs supporting a more balanced risk-reward profile, RBC Capital Markets said in a note. RBC maintained its sector perform rating on the stock and raised its price target to $38 from $35. Moderna shares rose 4.6%.